HUP0402236A2 - Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0402236A2
HUP0402236A2 HU0402236A HUP0402236A HUP0402236A2 HU P0402236 A2 HUP0402236 A2 HU P0402236A2 HU 0402236 A HU0402236 A HU 0402236A HU P0402236 A HUP0402236 A HU P0402236A HU P0402236 A2 HUP0402236 A2 HU P0402236A2
Authority
HU
Hungary
Prior art keywords
hydrogen
general formula
compounds
formula
carbon atoms
Prior art date
Application number
HU0402236A
Other languages
English (en)
Inventor
Andrew Thomas Bach
Prasad Koteswara Kapa
George Tien-San Lee
Eric M. Loeser
Michael Lloyd Sabio
James Lawrence Stanton
Thalaththani Ralalage Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0402236A2 publication Critical patent/HUP0402236A2/hu
Publication of HUP0402236A3 publication Critical patent/HUP0402236A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A jelen találmány az (I) általános képletű vegyületekre vonatkozikmely képletben L jelentése (II) általános képletű gyök, mely képletbenR1 jelentése előnyösen hidrogén, adott esetben szubsztituált alkil-,arilcsoport; R2 jelentése előnyösen hidrogén, hidroxi-, adott esetbenszubsztituált alkil-, arilcsoport; R3 jelentése előnyösen hidrogénvagy arilcsoport. n jelentése nulla, 1 vagy 2; Y jelentése hidrogén;R4 jelentése hidrogén; vagy R4 és Y a szénatomokkal együtt, amelyekhezkapcsolódnak egy kötést képeznek, azzal a megkötéssel, hogy njelentése 1 és R2 és R3 a szénatomokkal együtt, amelyekhezkapcsolódnak egy kötést képeznek; vagy L jelentése (III) általánosképletű gyök, mely képletben R" jelentése hidrogén, halogén, adottesetben szubsztituált alkil- vagy alkoxicsoport; m jelentése 1 vagy 2;R4 jelentése hidrogén; vagy R4 és Y a szénatomokkal együtt, amelyekhezkapcsolódnak egy vegyértékkötést képeznek, azzal a megkötéssel, hogy mjelentése l; R és R' jelentése előnyösen egymástól függetlenülhidrogén, halogén, X jelentése -Z-(CH2)P-Q-W. A találmány tárgyátképezi, továbbá az (I) általános képletű vegyületek gyógyászatilagelfogadható sói, vagy ezek egy optikai izomerje, vagy az optikaiizomerek elegye. A találmány tárgyát képezik továbbá az (I) általánosképletű vegyületeket tartalmazó gyógyszerkészítmények. Az (I)általános képletű vegyületek a peroxiszóma proliferátor-aktiváltreceptorok (PPAR) potenciális agonistái. Ennek megfelelően a jelentalálmány szerinti vegyületek hasznosak a PPAR receptor aktivitássalösszefüggő állapotok, így például diszlipidémia, hiperlipidémia,hiperkoleszterémia kezelésére. Ó
HU0402236A 2001-11-21 2002-11-20 Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof HUP0402236A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33198601P 2001-11-21 2001-11-21
US39690602P 2002-07-18 2002-07-18
PCT/EP2002/013025 WO2003043985A1 (en) 2001-11-21 2002-11-20 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
HUP0402236A2 true HUP0402236A2 (hu) 2005-02-28
HUP0402236A3 HUP0402236A3 (en) 2010-03-29

Family

ID=38460593

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402236A HUP0402236A3 (en) 2001-11-21 2002-11-20 Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof

Country Status (30)

Country Link
US (4) US7183304B2 (hu)
EP (1) EP1448523B1 (hu)
JP (2) JP4171700B2 (hu)
KR (1) KR100607019B1 (hu)
CN (2) CN100429201C (hu)
AR (1) AR037655A1 (hu)
AT (1) ATE370931T1 (hu)
AU (1) AU2002352073B8 (hu)
BR (1) BR0214305A (hu)
CA (1) CA2463154C (hu)
CO (1) CO5590897A2 (hu)
DE (1) DE60222006T2 (hu)
DK (1) DK1448523T3 (hu)
EC (1) ECSP045103A (hu)
ES (1) ES2290345T3 (hu)
HK (1) HK1068874A1 (hu)
HU (1) HUP0402236A3 (hu)
IL (1) IL161258A0 (hu)
MX (1) MXPA04004869A (hu)
MY (1) MY134965A (hu)
NO (1) NO327255B1 (hu)
NZ (1) NZ532080A (hu)
PE (1) PE20030565A1 (hu)
PL (1) PL368637A1 (hu)
PT (1) PT1448523E (hu)
RU (1) RU2345983C2 (hu)
SI (1) SI1448523T1 (hu)
TW (1) TW200303742A (hu)
WO (1) WO2003043985A1 (hu)
ZA (1) ZA200402310B (hu)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520226A (ja) † 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
ES2311117T3 (es) * 2002-12-10 2009-02-01 Novartis Ag Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
DE10300099A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PE20050157A1 (es) * 2003-05-20 2005-05-17 Novartis Ag Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
WO2005005421A1 (en) * 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
DE10335449A1 (de) * 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
FR2869904B1 (fr) * 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
RU2007131501A (ru) * 2005-01-18 2009-02-27 Новартис АГ (CH) Способы применения двойных агонистов ppar и устройств для доставки лекарственных средств, содержащих такие соединения
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
EP1893583B1 (en) 2005-05-31 2012-04-04 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
GT200600302A (es) * 2005-07-13 2007-03-19 Agonistas de ppara/y y procesos de preparación
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2647819C (en) 2006-03-31 2012-12-11 Novartis Ag Phenylcyclohexyl derivatives as dgat1 inhibitors
TW200806627A (en) 2006-04-11 2008-02-01 Novartis Ag Organic compounds
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
CN101454004B (zh) 2006-04-18 2013-12-04 阿迪亚生命科学公司 作为mek抑制剂的吡啶酮磺酰胺类和吡啶酮硫酰胺类
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2175885B1 (en) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
US9305735B2 (en) 2007-09-28 2016-04-05 Brigham Young University Reinforced polymer x-ray window
US8498381B2 (en) 2010-10-07 2013-07-30 Moxtek, Inc. Polymer layer on X-ray window
US8736138B2 (en) 2007-09-28 2014-05-27 Brigham Young University Carbon nanotube MEMS assembly
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8703761B2 (en) 2008-07-15 2014-04-22 Novartis Ag Organic compounds
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8247971B1 (en) 2009-03-19 2012-08-21 Moxtek, Inc. Resistively heated small planar filament
WO2010108652A1 (en) 2009-03-27 2010-09-30 Ardea Biosciences Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
WO2010114636A1 (en) * 2009-04-03 2010-10-07 Mount Sinai School Of Medicine Of New York University Compositions for treatment of alzheimer's disease
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
KR20120092629A (ko) 2009-10-09 2012-08-21 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
IN2012DN03312A (hu) * 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US7983394B2 (en) 2009-12-17 2011-07-19 Moxtek, Inc. Multiple wavelength X-ray source
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8526574B2 (en) 2010-09-24 2013-09-03 Moxtek, Inc. Capacitor AC power coupling across high DC voltage differential
KR101900652B1 (ko) 2010-10-07 2018-09-19 노파르티스 아게 （4-｛4-［5-（6-트리플루오로메틸-피리딘-3-일아미노）-피리딘-2-일］-페닐｝-시클로헥실）-아세트산의 나트륨 염의 신규 결정형
EP2663308A1 (en) 2011-01-13 2013-11-20 Novartis AG Bace-2 inhibitors for the treatment of metabolic disorders
EA024059B1 (ru) 2011-01-13 2016-08-31 Новартис Аг Гетероциклические производные и их применение в лечении неврологических расстройств
US8804910B1 (en) 2011-01-24 2014-08-12 Moxtek, Inc. Reduced power consumption X-ray source
US8750458B1 (en) 2011-02-17 2014-06-10 Moxtek, Inc. Cold electron number amplifier
US8929515B2 (en) 2011-02-23 2015-01-06 Moxtek, Inc. Multiple-size support for X-ray window
US8792619B2 (en) 2011-03-30 2014-07-29 Moxtek, Inc. X-ray tube with semiconductor coating
EP2697240B1 (en) 2011-04-14 2015-09-16 Novartis AG Glycoside derivatives and uses thereof
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
US8989354B2 (en) 2011-05-16 2015-03-24 Brigham Young University Carbon composite support structure
US9076628B2 (en) 2011-05-16 2015-07-07 Brigham Young University Variable radius taper x-ray window support structure
US9174412B2 (en) 2011-05-16 2015-11-03 Brigham Young University High strength carbon fiber composite wafers for microfabrication
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
MX2014004479A (es) 2011-10-13 2014-08-01 Novartis Ag Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
MX2014006409A (es) 2011-11-28 2014-07-30 Novartis Ag Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US8761344B2 (en) 2011-12-29 2014-06-24 Moxtek, Inc. Small x-ray tube with electron beam control optics
MX357768B (es) 2012-04-27 2018-07-24 Novartis Ag Inhibidores de dgat1 de eter ciclico de cabeza de puente.
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
KR20150103747A (ko) 2013-01-11 2015-09-11 노파르티스 아게 2-((1r,4r)-4-(4-(5-(벤족사졸-2-일아미노)피리딘-2-일)페닐)시클로헥실)아세트산의 메글루민 염 형태 및 dgat1 억제제로서의 그의 용도
US9173623B2 (en) 2013-04-19 2015-11-03 Samuel Soonho Lee X-ray tube and receiver inside mouth
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
JP7362611B2 (ja) 2017-12-14 2023-10-17 ユニヴェルシテ・ドゥ・ストラスブール 非アルコール性脂肪肝疾患及び線維症の治療及び予防のためのペプチド
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
EP3887388A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
LT3897697T (lt) 2018-12-21 2023-07-10 Université De Strasbourg Peptidai, skirti diabeto ir susijusių sutrikimų gydymui ir profilaktikai
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8525578D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Heterocyclic compounds
JP2606735B2 (ja) * 1988-02-19 1997-05-07 石原産業株式会社 ２―アミノ―４，６―ジクロロピリミジンの製造方法
US5036153A (en) * 1989-05-11 1991-07-30 Braish Tamim F Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
IE70217B1 (en) * 1990-08-15 1996-10-30 British Bio Technology Benzimidazole derivatives process for their preparation and application
DE4206045A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
US5795890A (en) 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
FR2765222B1 (fr) * 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
CO5011105A1 (es) * 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
FR2790260B1 (fr) * 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Also Published As

Publication number Publication date
BR0214305A (pt) 2004-10-26
DK1448523T3 (da) 2007-12-27
DE60222006T2 (de) 2008-04-30
KR20050044556A (ko) 2005-05-12
TW200303742A (en) 2003-09-16
CN101362731B (zh) 2011-01-19
JP2009024001A (ja) 2009-02-05
SI1448523T1 (sl) 2008-02-29
US20040248936A1 (en) 2004-12-09
RU2004119037A (ru) 2006-01-10
PT1448523E (pt) 2007-11-26
AR037655A1 (es) 2004-12-01
MXPA04004869A (es) 2005-04-11
KR100607019B1 (ko) 2006-08-01
RU2345983C2 (ru) 2009-02-10
EP1448523A1 (en) 2004-08-25
DE60222006D1 (de) 2007-10-04
CN100429201C (zh) 2008-10-29
CN101362731A (zh) 2009-02-11
ATE370931T1 (de) 2007-09-15
AU2002352073B2 (en) 2006-10-19
US20070135502A1 (en) 2007-06-14
IL161258A0 (en) 2004-09-27
PL368637A1 (en) 2005-04-04
ECSP045103A (es) 2004-06-28
US20090118160A1 (en) 2009-05-07
CN1589260A (zh) 2005-03-02
ZA200402310B (en) 2005-01-05
CA2463154A1 (en) 2003-05-30
CO5590897A2 (es) 2005-12-30
AU2002352073A1 (en) 2003-06-10
PE20030565A1 (es) 2003-08-14
JP4171700B2 (ja) 2008-10-22
ES2290345T3 (es) 2008-02-16
CA2463154C (en) 2012-02-14
NZ532080A (en) 2006-08-31
AU2002352073B8 (en) 2006-11-09
HK1068874A1 (en) 2005-05-06
HUP0402236A3 (en) 2010-03-29
US7183304B2 (en) 2007-02-27
MY134965A (en) 2008-01-31
EP1448523B1 (en) 2007-08-22
JP2005511634A (ja) 2005-04-28
NO327255B1 (no) 2009-05-25
NO20042147L (no) 2004-05-25
US20110251171A1 (en) 2011-10-13
WO2003043985A1 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
HUP0402236A2 (hu) Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO981496D0 (no) Imidazolderivater med affinitet for <alfa> 2 reseptoraktivitet
TW274547B (hu)
HUP0200248A2 (hu) Pajzsmirigy-receptor ligandumként alkalmazható oxámsavszármazékok, azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint alkalmazásuk
DE69331190T2 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
AU3345595A (en) 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
NZ515408A (en) 5-phenyl-pyrimidine derivatives
HUP0301272A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
ATE297929T1 (de) Azabicycloalkan-derivate zur verwendung als inhibitoren der serotonin-wiederaufnahme und als 5ht2a antagonisten
FI945581A (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater
HUP0001093A2 (hu) 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JO2261B1 (en) Derivatives 4 - Phenylbarmidine
HUP0200121A2 (hu) Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE116974T1 (de) 5- piperazinylalkyl-1,5-benzothiazepinone verwendbar als calciumantagonisten.
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
ATE216883T1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
DK1178047T3 (da) Diazabicyclooctanderivater og terapeutiske anvendelser deraf
DE60020246D1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
YU16196A (sh) Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka
RU95110868A (ru) Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция
NO20020475L (no) 2-aminotetralinderivater for terapi av glaukom
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP0203222A2 (hu) Szubsztituált benziltiazolidin-2,4-dion-származékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees